Merck & Co.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
The Phase III trial on a potential treatment for mild-to-moderate COVID-19 symptoms by Merck and Ridgeback Biotherapeutics showed promise in preventing hospitalizations and death.
Merck will acquire Acceleron for the expected $180 per share in cash for an approximate total equity value of $11.5 billion.
Reports emerged late Wednesday afternoon that Merck emerged as the winning suitor with a deal valued at about $11 billion.
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
The rumors had already been percolating as Acceleron’s stock has risen over the past 10 days from $130-a-share in mid-September to $167.65 as the market closed on Friday.
Diabetes player Novo Nordisk cut a deal this week, announcing a settlement agreement to put an end to a lawsuit filed in January 2017 by American Depository Receipt investors.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
During the past two years, fundraising and investment in biotechnology have reached record levels.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
JOBS
IN THE PRESS